OneSource Specialty Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ONESOURCE, BSE:544292 OneSource Specialty Pharma Ltd.

Search Inside the pdf :

OneSource Specialty Pharma Ltd.

06 Sep 2026

1508.00

-0.89%

Transiting from order book built up to commercial execution

Buy: OneSource Specialty Pharma...

ICICI Securities Limited

We recently visited OneSource’s drug-device combination (DDC) manufacturing plant in Bangalore. OneSource is the only CDMO with generic semaglutide approvals across the G7 nations.

Number of FII/FPI investors increased from 207 to 222 in Jun 2026 qtr.

OneSource Specialty Pharma Ltd.

26 Jul 2026

1508.00

-0.89%

Growth ingredients set in place

Buy: OneSource Specialty Pharma...

Target

ICICI Securities Limited

Q1FY27 marks the beginning of commercial supplies of generic semaglutide for OneSource, leading to strong growth of 37.2%/39.4%/63% in revenue/EBITDA/PAT, respectively.

Number of FII/FPI investors increased from 207 to 222 in Jun 2026 qtr.

OneSource Specialty Pharma Ltd.

13 Nov 2025

1508.00

-0.89%

GLP-1 story delayed not derailed

Buy: OneSource Specialty Pharma...

ICICI Securities Limited

Delay in generic semaglutide approvals from Canadian regulator may shift the launch timeline by a quarter; however, with a few customers securing the approval in India and approvals in Brazil and Saudi Arabia expected to flow in, OneSource’s management remains confident of the upcoming opportunity, and hence, maintains FY28 guidance for its base business.